Prot #CNTO1275PSO3013: A Phase 3 Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Subjects ≥6 to <12 Years of Age

Project: Research project

Project Details

StatusFinished
Effective start/end date2/21/17 → 12/31/22

Funding

  • Janssen Research & Development, LLC (Prot #CNTO1275PSO3013)